A -- MICROBIOLOGICAL TUBERCULOSIS DRUG SCREENING

Notice Date

September 8, 2000

Contracting Office

National Institutes of Health, National Institute of Allergy and Infectious Diseases, Contract Management Branch, Room 2230, 6700-B Rockledge Drive, MSC 7612, Bethesda, MD 20892-7612

ZIP Code

20892-7612

Solicitation Number

RFP-NIH-NIAID-DAIDS-01-13

Response Due

January 5, 2000

Point of Contact

Mr. Eric Young, Contract Specialist, 301-496-8371

E-Mail Address

Eric Young (cy39g@nih.gov)

Description

The NIAID, NIH has a requirement for the support of its mission to stimulate research towards discovery of improved therapies for tuberculosis, an opportunistic infection associated with the acquired immunodeficiency syndrome (AIDS) and an increasing health risk to the general population. The rising incidence of tuberculosis, particularly in conjunction with the spread of human immunodeficiency virus (HIV), has contributed to a public health emergency. The emergence of multidrug resistant tuberculosis has produced sizable medical challenges to the treatment and containment of infectious tuberculosis in the face of limited chemotherapeutic options. In order to facilitate the development of improved drugs for the treatment of tuberculosis, and particularly multi-drug resistant tuberculosis, the NIAID requires the directed acquisition and evaluation of selected novel synthetic and pure natural product compounds as potential tuberculosis antimicrobials. It is envisioned that compounds will be submitted under confidentiality agreements by pharmaceutical houses or research institutions in exchange for microbiological information on the relative potency of their compounds against Mycobacterium tuberculosis. The goal of this effort will be to encourage the rapid and efficient exploration of new classes of compounds for development as potential anti-tuberculosis agents. This solicitation will contain two parts, with a separate work statement for each part. Offerors shall submit completely separate proposals in response to Part A and/or Part B. Offerors may respond to more than one Part, but must submit separate Technical and Business proposals for each (under separate cover) to be considered. For each Part, separate Technical Evaluation Criteria will apply and separate competitive ranges will be determined. If submitting for both Parts, offerors must clearly describe how work under each Part will be coordinated. Part A and Part B proposals will be evaluated independently. Hence, up to two contracts are planned to be awarded. Three existing contracts provide the facility for coordinating acquisition and data management, for animal efficacy testing, and for technology transfer, respectively. The contract awarded under Part A of this solicitation will serve as the central facility for microbiological in vitro testing of novel compounds. The contract awarded under Part B of this solicitation will provide advanced testing of large compound libraries using high-throughput formats and specialized (biochemical target-directed) assays and is likely to serve as a pre-screen for Part A. These five contracts will be highly interactive, will exchange data at least monthly, and will formulate directions for testing in conjunction with the Project Officer. Solicitation RFP-NIH-NIAID-DAIDS-01-13 is due to be released on or about Monday, September 25, 2000.

Web Link

NIAID Home Page (http://www.niaid.nih.gov/contract)

Record

Loren Data Corp. 20000912/ASOL004.HTM (W-252 SN494631)